Structure Therapeutics (GPCR) Income towards Parent Company (2022 - 2026)

Structure Therapeutics' Income towards Parent Company history runs 5 years deep, the most recent figure standing at -$76.0 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 62.21% year-over-year to -$76.0 million; the TTM figure through Mar 2026 stood at -$25.6 million (up 15.47% YoY), while the FY2025 annual figure was $3.6 million, up 137.9% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$76.0 million, down from $177.8 million in the prior quarter.
• The five-year high for Income towards Parent Company was $177.8 million in Q4 2025, with the low at -$76.0 million in Q1 2026.
• The 5-year median for Income towards Parent Company is -$23.3 million (2023), against an average of -$5.8 million.
• Peak annual rise in Income towards Parent Company reached 132.06% in 2025, while the deepest fall reached 136.85% in 2025.
• Structure Therapeutics' Income towards Parent Company stood at $32.3 million in 2022, then soared by 72.31% to $55.7 million in 2023, then soared by 37.55% to $76.6 million in 2024, then soared by 132.06% to $177.8 million in 2025, then slumped by 142.73% to -$76.0 million in 2026.
• Business Quant data shows GPCR's Income towards Parent Company at -$76.0 million in Q1 2026, $177.8 million in Q4 2025, and -$65.7 million in Q3 2025.